Testing a modified Pap test to encourage cervical cancer screening
Tests a changed Pap test ending in women aged 25 and older.
Plain-language title generated from the registry record
Registry title: Ameliorated Pap Tests and Cervical Cancer Screening Participation
Key facts
- Where
- Douliu, Hsinchu, and Taipei, TaiwanSee the 5 sites
Where in Taiwan
- National Taiwan University Hospital Yunlin BranchDouliu, TaiwanTaking people
- National Taiwan University Hospital Hsin Chu BranchHsinchu, TaiwanTaking people
- National Taiwan University Cancer CenterTaipei, TaiwanTaking people
- National Taiwan University HospitalTaipei, TaiwanTaking people
- National Taiwan University Hospital Beihu BranchTaipei, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Taiwan University Hospital
- Trial code
- NCT06968871
- Record updated
- 30 October 2026
- Original description
The Pap test plays a crucial role in the early detection of cervical cancer. A pilot single-center randomized controlled trial applied the peak-end concept and added a non-painful step at the end of Pap smear screening, aimed to reduce recalled pain. However, there is still no multicenter study investigating the effect of the modified Pap test on cervical cancer screening participation.Read full original descriptionShow less
Effects of the Ameliorated Pap Test on Cervical Cancer Screening Participation: a Multicenter Randomized Controlled Trial
The Pap test plays a crucial role in the early detection of cervical cancer. A pilot single-center randomized controlled trial applied the peak-end concept and added a non-painful step at the end of Pap smear screening, aimed to reduce recalled pain. However, there is still no multicenter study investigating the effect of the modified Pap test on cervical cancer screening participation.
The present project is the first multicenter randomized controlled trial to expand the current scope of the peak-end theory into Pap tests and cervical cancer screening participation by adding a non-painful step at the end of Pap smear screening. Our multidisciplinary team (NTUH Pap Study Group) aims to provide innovative, feasible, and low-cost strategies for cervical cancer screening participation.
Inclusion: Women aged 25 or above.
Exclusion: Any active cancer at study entry (defined as cancer diagnosed or treated within the previous 6 months, recurrent, regionally advanced or metastatic cancer); Previous hysterectomy, pelvic surgery, or radiotherapy; Active vaginal or uterus infection; Ongoing menstruation; Pregnancy; Incapability of understanding the numeric pain scales; Analgesic use within 24 hours.